Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed ...

Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 18th. HC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: February 21 at 7:59:35 PM EST ...

华盛顿特区讯 — 根据最新提交给美国证券交易委员会的文件显示，Vanda制药公司（NASDAQ:VNDA）总裁兼首席执行官Mihael Hristos Polymeropoulos于2月25日以加权平均价格4.464美元购入了10,000股公司普通股 ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company with a market capitalization of $262 million and impressive gross margins of 94%, disclosed recent changes ...